Interleukin-10 controls the protective effects of circulating microparticles from patients with septic shock on tissue-engineered vascular media by H.Ahmed Mostefai et al.
Interleukin-10 controls the protective effects of circulating
microparticles from patients with septic shock on tissue-
engineered vascular media
Submitted by Emmanuel Lemoine on Tue, 02/24/2015 - 15:42
Titre Interleukin-10 controls the protective effects of circulating microparticles frompatients with septic shock on tissue-engineered vascular media
Type de
publication Article de revue
Auteur
Mostefai, H. A [1], Bourget, J. M [2], Meziani, F. [3], Martinez, Maria Carmen [4],
Leonetti, Daniela [5], Mercat, Alain [6], Asfar, Pierre [7], Germain, L. [8],
Andriantsitohaina, Ramaroson [9]
Editeur Portland Press











Aged [10], Animals [11], Cell-Derived Microparticles/physiology [12], Female [13],
Histamine/physiology [14], Humans [15], Interleukin-10/metabolism [16],
Lipopolysaccharides [17], Male [18], Mice [19], Middle Aged [20], Muscle, Smooth,
Vascular/physiopathology [21], Myocytes, Smooth Muscle/physiology [22], Oxidative
Stress [23], RNA, Messenger/metabolism [24], Sepsis/physiopathology [25],
Shock/metabolism [26], tissue engineering [27], Umbilical Arteries/cytology [28]
Résumé en
anglais
During sepsis, inflammation can be orchestrated by the interaction between
circulating and vascular cells that, under activation, release MPs (microparticles).
Previously, we reported that increased circulating MPs in patients with sepsis play a
pivotal role in ex vivo vascular function suggesting that they are protective against
vascular hyporeactivity. The present study was designed to investigate the effects of
MPs from patients with sepsis on the contractile response of TEVM (tissue-
engineered vascular media). TEVM that were composed only of a media layer were
produced by tissue engineering from human arterial SMCs (smooth muscle cells)
isolated from umbilical cords. TEVM was incubated with MPs isolated from whole
blood of 16 patients with sepsis. TEVM were incubated for 24 h with MPs and used
for the study of vascular contraction, direct measurements of NO and O2-
(superoxide anion) production by EPR and quantification of mRNA cytokine
expression. MPs from patients with sepsis increased contraction induced by
histamine in TEVM. This effect was not associated with inflammation, neither linked
to the activation of NF-kappaB (nuclear factor kappaB) pathway nor to the increase
in iNOS (inducible NO synthase) and COX (cyclo-oxygenase)-2 expression. In
contrast, mRNA expression of IL (interleukin)-10 was enhanced. Then, we
investigated the effect of IL-10 on vascular hyporeactivity induced by LPS
(lipopolysaccharide). Although IL-10 treatment did not modify the contractile
response in TEVM by itself, this interleukin restored contraction in LPS-treated
TEVM. In addition, IL-10 treatment both prevented vascular hyporeactivity induced
by LPS injection in mice and improved survival of LPS-injected mice. These findings
show an association between the capacity of MPs from patients with sepsis to restore
vascular hyporeactivity induced by LPS and their ability to increase IL-10 in the
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